Literature DB >> 17388698

Manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by the free thiol form of amifostine and tumor necrosis factor alpha.

Jeffrey S Murley1, Yasushi Kataoka, Kenneth L Baker, Alan M Diamond, William F Morgan, David J Grdina.   

Abstract

RKO36 cells, a subclone of RKO colorectal carcinoma cells that have been stably transfected with the pCMV-EGFP2Xho vector, were grown to confluence and then exposed to either the radioprotector WR-1065, i.e. the active thiol form of amifostine, for 30 min at doses of 40 microM and 4 mM or the cytokine tumor necrosis factor alpha (TNFalpha, TNFA) for 30 min at a concentration of 10 ng/ml and then washed. Total protein was isolated as a function of time up to 32 h after these treatments. Both doses of WR-1065 as well as the concentration of TNFalpha used were effective in elevating intracellular levels of the antioxidant protein SOD2 (also known as MnSOD) at least 15-fold over background levels as determined by Western blot analysis, while measured SOD2 activity was elevated between 5.5- and 6.9-fold. SOD2 reached a maximal level 24 h and 20 h after WR-1065 and TNFalpha treatments, respectively. The antioxidant proteins catalase and glutathione peroxidase (GPX) were also monitored over the 32-h period. In contrast to the robust changes observed in intracellular levels of SOD2 as a function of time after exposure of cells to WR-1065, catalase levels were elevated only 2.6-fold over background as determined by Western blot analysis, while GPX activity was unaffected by WR-1065 exposure. GPX protein levels were extremely low in cells, and analysis of GPX activity using a spectrophotometric method based on the consumption of reduced NADPH also revealed no measurable change as a function of WR-1065 or TNFalpha exposure. RKO36 cells either were irradiated with X rays in the presence of either 40 microM or 4 mM WR-1065 or 10 ng/ml TNFalpha or were irradiated 24 or 20 h later, respectively, when SOD2 protein levels were most elevated. The concentrations and exposure conditions used for WR-1065 and TNFalpha were not cytotoxic and had no effect on plating efficiencies or cell survival compared to untreated controls. No protection or sensitization was observed for cells irradiated in the presence of 40 microM WR-1065 or TNFalpha. Survival was elevated 1.90-fold for cells irradiated in the presence of 4 mM WR-1065. When RKO36 cells were irradiated with 2 Gy 24 h after 40 microM or 4 mM WR-1065 and 20 h after TNFalpha treatments when SOD2 levels were the most increased, survival was elevated 1.42-, 1.48- and 1.36-fold, respectively. This increased survival represents a SOD2-mediated delayed radioprotective effect. SOD2 appears to be an important antioxidant gene whose inducible expression is an important element in adaptive cellular responses in general, and the delayed radioprotective effect in particular. It can be induced by a range of agents including cytoprotective nonprotein thiols such as WR-1065 and pleiotropic cytokines such as TNFalpha.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388698     DOI: 10.1667/RR0758.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  24 in total

Review 1.  Modifying radiation damage.

Authors:  Kwanghee Kim; William H McBride
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

2.  SOD2-mediated effects induced by WR1065 and low-dose ionizing radiation on micronucleus formation in RKO human colon carcinoma cells.

Authors:  Jeffrey S Murley; Yasushi Kataoka; Richard C Miller; Jian Jian Li; Gayle Woloschak; David J Grdina
Journal:  Radiat Res       Date:  2010-11-08       Impact factor: 2.841

3.  Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response.

Authors:  David J Grdina; Jeffrey S Murley; Yasushi Kataoka; Kenneth L Baker; Rangesh Kunnavakkam; Mitchell C Coleman; Douglas R Spitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-01       Impact factor: 7.038

4.  SOD2-mediated adaptive responses induced by low-dose ionizing radiation via TNF signaling and amifostine.

Authors:  J S Murley; K L Baker; R C Miller; T E Darga; R R Weichselbaum; D J Grdina
Journal:  Free Radic Biol Med       Date:  2011-09-03       Impact factor: 7.376

5.  Protective effect of an antithyroid compound against γ-radiation-induced damage in human colon cancer cells.

Authors:  Marina Perona; Maria A Dagrosa; Romina Pagotto; Mariana Casal; Omar Pignataro; Mario A Pisarev; Guillermo J Juvenal
Journal:  Radiat Environ Biophys       Date:  2014-05-09       Impact factor: 1.925

Review 6.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

Review 7.  MnSOD in oxidative stress response-potential regulation via mitochondrial protein influx.

Authors:  Demet Candas; Jian Jian Li
Journal:  Antioxid Redox Signal       Date:  2013-06-08       Impact factor: 8.401

8.  Evaluation of the fullerene compound DF-1 as a radiation protector.

Authors:  Aaron P Brown; Eun Joo Chung; Mary Ellen Urick; William P Shield; Anastasia L Sowers; Angela Thetford; Uma T Shankavaram; James B Mitchell; Deborah E Citrin
Journal:  Radiat Oncol       Date:  2010-05-11       Impact factor: 3.481

9.  Amifostine metabolite WR-1065 disrupts homologous recombination in mammalian cells.

Authors:  Jaroslaw Dziegielewski; Wilfried Goetz; Jeffrey S Murley; David J Grdina; William F Morgan; Janet E Baulch
Journal:  Radiat Res       Date:  2010-02       Impact factor: 2.841

10.  Manganese superoxide dismutase interacts with a large scale of cellular and mitochondrial proteins in low-dose radiation-induced adaptive radioprotection.

Authors:  Angela Eldridge; Ming Fan; Gayle Woloschak; David J Grdina; Brett A Chromy; Jian Jian Li
Journal:  Free Radic Biol Med       Date:  2012-09-06       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.